



Ziyuanyuan Holdings Group Limited

紫元元控股集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 8223)

**THIRD QUARTERLY RESULTS ANNOUNCEMENT
FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2023**

**CHARACTERISTICS OF GEM OF THE STOCK EXCHANGE OF HONG KONG
LIMITED (THE “STOCK EXCHANGE”)**

GEM has been positioned as a market designed to accommodate small and mid-sized companies to which a higher investment risk may be attached than other companies listed on the Stock Exchange. Prospective investors should be aware of the potential risks of investing in such companies and should make the decision to invest only after due and careful consideration.

Given that the companies listed on GEM are generally small and mid-sized companies, there is a risk that securities traded on GEM may be more susceptible to high market volatility than securities traded on the Main Board of the Stock Exchange and no assurance is given that there will be a liquid market in the securities traded on GEM.

Hong Kong Exchanges and Clearing Limited and the Stock Exchange take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

*This announcement, for which the directors (the “**Directors**”) of Ziyuanyuan Holdings Group Limited (the “**Company**”) collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM of the Stock Exchange (the “**GEM Listing Rules**”) for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief, the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.*

The board of Directors (the “**Board**”) hereby announces the unaudited condensed consolidated financial results of the Company and its subsidiaries (the “**Group**”) for the three months and nine months ended 30 September 2023 (the “**Period**”), together with the comparative unaudited figures for the corresponding period in 2022 (the “**Prior Period**”), as follows:

CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

For the three months and nine months ended 30 September 2023

	Notes	Three months ended		Nine months ended	
		30.9.2023 RMB'000 (Unaudited)	30.9.2022 RMB'000 (Unaudited)	30.9.2023 RMB'000 (Unaudited)	30.9.2022 RMB'000 (Unaudited)
Revenue					
Finance leasing income		1,827	11,295	14,702	30,612
Interest income from loan receivables		1	4	7	525
Income from postpartum care services		7,434	16,204	23,005	40,916
Income from trading of medical equipment and consumables		56,394	65,711	203,565	163,627
Total revenue	3	65,656	93,214	241,279	235,680
Cost of sales		(37,891)	(60,264)	(155,320)	(141,138)
Bank interest income		7	26	36	83
Other gains and losses	4	663	743	886	3,713
Staff costs	8	(10,974)	(10,533)	(31,686)	(31,172)
Impairment losses under expected credit loss (“ECL”) model, net of reversal	5	(476)	(914)	(2,222)	(4,550)
Other operating expenses		(10,571)	(17,510)	(31,582)	(41,895)
Finance costs	6	(3,205)	(3,452)	(10,846)	(9,713)
Profit before income tax		3,209	1,310	10,545	11,008
Income tax expenses	7	(10)	(230)	(1,582)	(1,993)
Profit and total comprehensive income for the period	8	3,199	1,080	8,963	9,015
Profit and total comprehensive income for the period attributable to:					
Owners of the Company		3,467	930	9,582	9,033
Non-controlling interests		(268)	150	(619)	(18)
		3,199	1,080	8,963	9,015
Earnings per share for profit attributable to owners of the Company during the period					
– Basic and diluted (RMB cents)	10	0.867	0.233	2.396	2.258

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

For the nine months ended 30 September 2023

	Attributable to owners of the Company						Non-	Total
	Share capital	Share premium	Capital and other reserves	Statutory reserves	Retained profits	Total	controlling	
							interests	
	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	
At 1 January 2023 (audited)	33,839	56,743	133,023	11,543	71,713	306,861	3,956	310,817
Profit and total comprehensive income for the period	-	-	-	-	9,582	9,582	(619)	8,963
Dividends paid (Note 9)	-	(8,977)	-	-	-	(8,977)	(415)	(9,392)
At 30 September 2023 (unaudited)	33,839	47,766	133,023	11,543	81,295	307,466	2,922	310,388
At 1 January 2022 (audited)	33,839	65,218	133,023	9,411	58,032	299,523	4,799	304,322
Profit and total comprehensive income for the period	-	-	-	-	9,033	9,033	(18)	9,015
Dividends paid (Note 9)	-	(8,475)	-	-	-	(8,475)	(456)	(8,931)
At 30 September 2022 (unaudited)	33,839	56,743	133,023	9,411	67,065	300,081	4,325	304,406

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

1. BASIS OF PREPARATION

The condensed consolidated financial statements have been prepared in accordance with Hong Kong Financial Reporting Standards (“**HKFRSs**”) issued by the Hong Kong Institute of Certified Public Accountants (the “**HKICPA**”) as well as with the applicable disclosure requirements of Chapter 18 of the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited.

2. PRINCIPAL ACCOUNTING POLICIES

The condensed consolidated financial statements have been prepared on the historical cost basis except for investment properties and certain financial instruments that are measured at fair values, as appropriate.

Other than additional accounting policies resulting from application of amendments to HKFRSs and application of certain accounting policies which became relevant to the Group, the accounting policies and method of computation used in the condensed consolidated financial statements for the nine months ended 30 September 2023 are the same as those presented in the Group’s annual financial statements for the year ended 31 December 2022.

Application of amendments to HKFRSs

In the current period, the Group has applied the new and amendments to HKFRSs issued by the HKICPA which are effective for the annual period beginning on or after 1 January 2023 for the preparation of the Group’s condensed consolidated financial statements.

The application of the amendments to HKFRSs in the current period has had no material impact on the Group’s financial positions and performance for the current and prior periods and/or on the disclosures set out in these condensed consolidated financial statements.

3. REVENUE

Revenue for the period represents finance leasing income, interest income from loan receivables, income from postpartum care services and income from trading of medical equipment and consumables in the PRC. The amounts of each significant category of revenue recognised in revenue during the period are as follows:

	Three months ended		Nine months ended	
	30.9.2023 <i>RMB'000</i> (Unaudited)	30.9.2022 <i>RMB'000</i> (Unaudited)	30.9.2023 <i>RMB'000</i> (Unaudited)	30.9.2022 <i>RMB'000</i> (Unaudited)
Revenue from other source				
Finance leasing income	1,827	11,295	14,702	30,612
Interest income from loan receivables	1	4	7	525
	<u>1,828</u>	<u>11,299</u>	<u>14,709</u>	<u>31,137</u>
Revenue from contracts with customers				
Income from postpartum care services	7,434	16,204	23,005	40,916
Income from trading of medical equipment and consumables	56,394	65,711	203,565	163,627
	<u>63,828</u>	<u>81,915</u>	<u>226,570</u>	<u>204,543</u>
	<u><u>65,656</u></u>	<u><u>93,214</u></u>	<u><u>241,279</u></u>	<u><u>235,680</u></u>

4. OTHER GAINS AND LOSSES, NET

	Three months ended		Nine months ended	
	30.9.2023	30.9.2022	30.9.2023	30.9.2022
	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
Fair value gain on other financial assets	5	516	9	3,044
Change in fair value of investment properties	–	–	(461)	–
Government subsidies	523	156	840	565
Exchange (loss)/gain, net	(53)	37	51	(17)
Rental income	102	–	151	–
Others	86	34	296	121
	<u>663</u>	<u>743</u>	<u>886</u>	<u>3,713</u>

5. IMPAIRMENT LOSSES UNDER ECL MODEL, NET OF REVERSAL

	Three months ended		Nine months ended	
	30.9.2023	30.9.2022	30.9.2023	30.9.2022
	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
Impairment losses recognised on:				
– Trade receivables	(111)	314	(890)	1,050
– Finance lease receivables	194	601	1,889	3,505
– Loan receivables	–	(1)	(1)	(5)
– Financial guarantee	393	–	1,224	–
	<u>476</u>	<u>914</u>	<u>2,222</u>	<u>4,550</u>

6. FINANCE COSTS

	Three months ended		Nine months ended	
	30.9.2023	30.9.2022	30.9.2023	30.9.2022
	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
Interests on bank and other borrowings	2,934	3,210	10,020	9,097
Imputed interests on interest-free deposits from finance lease customers	–	–	21	54
Interests on lease liabilities	271	242	805	562
	<u> </u>	<u> </u>	<u> </u>	<u> </u>
Total interest expense on financial liabilities not measured at fair value through profit or loss	3,205	3,452	10,846	9,713
	<u> </u>	<u> </u>	<u> </u>	<u> </u>

7. INCOME TAX EXPENSES

	Three months ended		Nine months ended	
	30.9.2023	30.9.2022	30.9.2023	30.9.2022
	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
The charge (credit) comprises:				
Current tax				
– PRC Enterprise Income Tax	49	1,097	1,472	3,646
Deferred tax	(39)	(867)	110	(1,653)
	<u> </u>	<u> </u>	<u> </u>	<u> </u>
	10	230	1,582	1,993
	<u> </u>	<u> </u>	<u> </u>	<u> </u>

8. PROFIT FOR THE PERIOD

Profit for the period has been arrived at after charging (crediting):

	Three months ended		Nine months ended	
	30.9.2023	30.9.2022	30.9.2023	30.9.2022
	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
Directors' emoluments	1,239	653	3,305	2,111
Other staff costs				
– Salaries, allowances and other staff benefits	9,271	9,550	26,663	27,663
– Staffs' retirement benefit scheme contributions	1,250	1,365	3,773	4,396
Total staff costs	11,760	11,568	33,741	34,170
Less: staff costs recognised as research and development costs in other operating expenses	(786)	(1,035)	(2,055)	(2,998)
Staff costs recognised in profit or loss	10,974	10,533	31,686	31,172
Amortisation of intangible assets	255	255	765	765
Cost of inventories sold	37,891	60,264	155,320	141,138
Depreciation of property, plant and equipment	928	970	2,939	3,725
Depreciation of right-of-use assets	2,170	2,661	6,538	6,663
Research and development costs recognised as an expense (included in other operating expenses)	1,106	351	2,442	787
Short-term leases payments	211	1,172	929	4,627

9. DIVIDENDS

During the current period, a final dividend of HK2.5 cents (nine months ended 30 September 2022: HK2.5 cents) per share in respect of the year ended 31 December 2022 was declared to the owners of the Company. The aggregate amounts of the final dividend were HK\$10,000,000 (equivalent to RMB8,977,000) (nine months ended 30 September 2022: HK\$10,000,000 (equivalent to RMB8,475,000)).

The directors of the Company do not recommend the payment of an interim dividend in respect of the nine months ended 30 September 2023 (nine months ended 30 September 2022: Nil).

10. EARNINGS PER SHARE

The calculation of basic earnings per share attributable to owners of the Company is based on the following data:

	Three months ended		Nine months ended	
	30.9.2023	30.9.2022	30.9.2023	30.9.2022
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
Earnings:				
Earnings for the purpose of basic earnings per share				
Profit for the period attributable to owners of the Company for the purpose of basic earnings per share (RMB'000)	<u>3,467</u>	<u>930</u>	<u>9,582</u>	<u>9,033</u>
Number of shares:				
Weighted average number of ordinary shares for the purpose of basic earnings per share ('000)	<u>400,000</u>	<u>400,000</u>	<u>400,000</u>	<u>400,000</u>

No diluted earnings per share are presented as there were no potential dilutive ordinary shares in issue during the three months and nine months ended 30 September 2022 and 2023.

MANAGEMENT DISCUSSION AND ANALYSIS

The Board of Directors of the Company announces the unaudited condensed consolidated quarterly results of the Group for the nine months ended 30 September 2023 together with the corresponding comparative figures.

BUSINESS REVIEW

For the nine months ended 30 September 2023, the Group is principally engaged in provision of medical equipment finance leasing services, maternal and child postpartum care industry services and trading of medical equipment and consumables business in the PRC.

Finance leasing services

During the Period, the Group has been focusing on provision of finance leasing services to SMEs customers in the medical equipment industry in various provinces, municipalities, and autonomous regions in the PRC, where the Group has established connections with industry players and gained operational expertise. The finance lease offered by the Group comprises direct finance leasing and sale-leaseback. The Group provided services to approximately 4,700 SMEs customers across 30 provinces, municipalities and autonomous regions in the PRC as at 30 September 2023. The Group recorded a revenue of RMB14.7 million from the finance leasing services during the Period.

Maternal and child postpartum care industry services

Postpartum confinement (坐月) is a traditional Chinese custom, which allows women to rest fully after giving birth, and to recover through diet. It is said that it is the best time for women to improve their physical well-being. Hence, centres for the provision of postpartum care services (月子中心) had emerged. The Group provided postpartum care services, consisting of four major areas of (i) health care for postpartum mothers and newborn babies; (ii) dietary and nutrition for postpartum mothers; (iii) recovery and beauty for postpartum mothers; and (iv) intellectual development for newborn babies.

Due to the restriction of the epidemic control measures, the Group's postpartum care centers were not able to operate normally during part of the Period, which made customers unable to check in on time and orders were returned, resulting in a decline in revenue in the maternal and child postpartum care industry services. The Group recorded a revenue of RMB23.0 million from the maternal and child postpartum care industry services during the Period.

Trading of medical equipment and consumables business

The Group expects that after the epidemic, the healthcare industry will become a new economic breakthrough with great potential for value addition. Benefiting from the PRC government's policy of encouraging innovation in medical equipment and promoting high quality development of the medical equipment industry, the Group has been able to leverage on its experience in the medical equipment industry from its previous finance leasing business, its cooperation with medical equipment suppliers and its practical understanding of the characteristics and needs of its customers to commence its medical equipment and consumables trading business in the PRC, mainly focusing on aesthetic medicine, dental, maternal and child and large hospital medical equipment. The Group recorded a revenue of RMB203.6 million from medical equipment and consumables trading business during the Period.

OUTLOOK

The Group is still reasonably optimistic to sustain the core business given all the economic uncertainties with the outbreak of Covid-19. The Group will continue to seek for the best possible opportunities to grow the Group's business by leveraging current client base. After the pandemic, the healthcare industry will be a new economic breakthrough with significant value-added potentials. The Group has preemptively set up the finance leasing service to focus on the field of medical equipment and to develop the trading of medical equipment and consumables business, which cooperates with the maternal and child postpartum care industry, to help upgrade the healthcare industry, but also to diversify the Group's income point.

In 2023, the global economic situation remains grim. We will continue to increase investment in various businesses and continue to strive to find opportunities in the face of challenges, so as to return shareholders and the public, and realize corporate value as well as social value.

FINANCIAL REVIEW

Revenue

Revenue consists of (i) finance leasing income and interest income from loan receivables in finance leasing services; (ii) postpartum care services income; and (iii) income from trading of medical equipment and consumables. For the Period, the Group's revenue increased by approximately RMB5.6 million or approximately 2.4%, from approximately RMB235.7 million for the Prior Period to approximately RMB241.3 million for the Period. The increase in revenue for the Period was mainly attributable to income from trading of medical equipment and consumables increased from approximately RMB163.6 million for the Prior Period to approximately RMB203.6 million for the Period, which offsetting (i) the finance leasing income decreased from approximately RMB31.1 million for the Prior Period to approximately RMB14.7 million for the Period; and (ii) postpartum care services income decreased from approximately RMB40.9 million for the Prior Period to approximately RMB23.0 million for the Period.

Cost of sales

For the Period, the cost of medical equipment and consumables sold increased to approximately RMB155.3 million (Prior Period: approximately RMB141.1 million).

Staff costs

Staff costs include primarily Directors' remuneration, employee salaries, allowances and other staff benefits as well as employee retirement benefits scheme contributions. Staff costs increased from RMB31.2 million for the Prior Period to approximately RMB31.7 million for the Period.

Impairment losses under expected credit loss ("ECL") model, net of reversal

The Group is not required to provide general provisions as commercial banks and other financial institutions which the China Banking Regulatory Commission regulates. The provisioning policies are based on the applicable accounting standards. The management assesses the measurement of ECL in relation to trade receivables, finance lease receivables, loan receivables and financial guarantee. In determining the impairment of trade receivables, finance lease receivables, loan receivables and financial guarantee, the management considers shared credit risk characteristics including industry types, historical past due information and lessees' creditworthiness for grouping, and assesses credit losses based on internal credit rating and on a forward looking basis with the use of appropriate models and assumptions relate to the economic inputs and the future macroeconomic conditions.

For the Period, an additional impairment loss of approximately RMB2.2 million (Prior Period: RMB4.5 million) was recognised due to the impact of Covid-19, which caused the increase in the customers' past due ratio.

Other operating expenses

Other operating expenses include primarily legal and professional fees, office supplies, depreciation of property, plant and equipment, depreciation of right-of-use assets, short-term leases payments, research and development costs, sales and marketing expenses and the miscellaneous expenses of postpartum care business. Other operating expenses decreased from approximately RMB41.9 million for the Prior Period to approximately RMB31.6 million for the Period. The decrease was mainly attributable to (i) the miscellaneous expenses of postpartum care business decreased from approximately RMB11.3 million for the Prior Period to approximately RMB4.2 million for the Period; (ii) short-term leases payments decreased from approximately RMB4.6 million for the Prior Period to approximately RMB1.1 million for the Period; and (iii) depreciation of property, plant and equipment decreased from approximately RMB3.7 million for the Prior Period to approximately RMB3.1 million for the Period, which offsetting sales and marketing expenses increased from RMB4.4 million to RMB6.7 million.

Finance costs

Finance costs consist of (i) imputed interests on interest-free deposits from finance lease customers; (ii) interests on bank and other borrowings; and (iii) interests on lease liabilities. Finance costs increased from approximately RMB9.7 million for the Prior Period to approximately RMB10.8 million for the Period. The increase was mainly due to the interest on bank and other borrowings increased from approximately RMB9.1 million for the Prior Period to approximately RMB10.0 million for the Period.

Income tax expenses

Certain PRC subsidiaries of the Group qualified as small low-profit enterprises with annual taxable income not more than RMB1.0 million, and the portion that exceeds RMB1.0 million but does not exceed RMB3.0 million (inclusive) are entitled to enterprise income tax calculated at 12.5% and 50% of its taxable income at a tax rate of 20%, respectively. A PRC subsidiary of the Group recognised as high technology enterprise is entitled to a preferential enterprise income tax rate of 15%. The enterprise income tax rate applicable to the other PRC subsidiaries of the Group is 25%.

Profit for the period attributable to owners of the Company

During the Period and Prior Period, the Group's profit and total comprehensive income attributable to owners of the Company were approximately RMB9.6 million and RMB9.0 million, respectively. The increase in profit and total comprehensive income attributable to owners of the Company during the Period was mainly attributable to the increase in income from trading of medical equipment and consumables.

Dividend

The Board of Directors of the Company does not recommend the payment of an interim dividend in respect of the Period (Prior Period: Nil).

CAPITAL STRUCTURE

The shares of the Company (the “**Shares**”) were successfully listed on the GEM of the Stock Exchange on 9 July 2018. There has been no change in the capital structure of the Group since then. The share capital of the Group only comprises ordinary Shares.

As at 30 September 2023, the Company’s issued share capital was HK\$40,000,000 and the number of its issued ordinary Shares was 400,000,000.

COMPETING INTEREST

During the nine months ended 30 September 2023, none of the Directors or the controlling shareholders of the Company or their respective close associates (as defined in the GEM Listing Rules) is interested in any business which competes or is likely to compete, either directly or indirectly, with the business of the Group or has any conflicts of interest with the Group.

DEED OF NON-COMPETITION

The controlling shareholders of the Company, namely Mr. Zhang Junshen (through Hero Global Limited), Mr. Zhang Junwei (through Icon Global Holding Limited), (the “**Controlling Shareholders**”) entered into a deed of non-competition dated 12 June 2018 (“**Deed of Non-competition**”) in favour of the Company (for itself and as trustee for each of its subsidiaries). For details of the Deed of Non-competition, please refer to the section headed “Relationship with Controlling Shareholders – Non-competition Undertaking” in the Prospectus. Each of the Controlling Shareholders has confirmed that none of them is engaged in, or interested in any business (other than the Group) which, directly or indirectly, competes or may compete with the business of the Group.

The independent non-executive Directors have also reviewed the status of compliance and confirmed that all the undertakings under the Deed of Non-competition have been complied with by each of the Controlling Shareholders since the nine months ended 30 September 2023 and up to the date of this announcement.

PURCHASE, SALES OR REDEMPTION OF THE COMPANY’S LISTED SECURITIES

Neither the Company nor any of its subsidiaries purchased, sold or redeemed any of the Company’s listed securities since the nine months ended 30 September 2023 and up to the date of this announcement.

CORPORATE GOVERNANCE PRACTICES

The Company considers the maintenance of a high standard of corporate governance important to the continuous growth of the Group. The Company’s corporate governance practices are based on code provisions as set out in the Corporate Governance Code (the “**CG Code**”) as contained in Appendix 15 of the GEM Listing Rules. Other than the deviation from code provision C.2.1, the Company has adopted and complied with, where applicable, the CG Code to ensure that the Group’s business activities and decision-making processes are regulated in a proper and prudent manner.

Up to the date of this announcement, other than the deviation from code provision C.2.1, the Company complied with the provisions of the CG Code as set out in Appendix 15 to the GEM Listing Rules.

CODE PROVISION C.2.1

In accordance with the code provision C.2.1 of the CG Code, the roles of chairman and chief executive officer should be separate and should not be performed by the same individual. The Board is of the view that although Mr. Zhang Junshen is the chairman and the chief executive officer of the Company, this structure will not impair the balance of power and authority between the Board and the management of the Company. The balance of power and authority is ensured by the operations of the Board, which comprises experienced and high caliber individuals and meets regularly to discuss issues affecting operations of the Company. The Board believes that this structure is conducive to strong and consistent leadership, enabling the Group to make and implement decisions promptly and efficiently. The Board has full confidence in Mr. Zhang Junshen and believes that his appointment to the posts of chairman and chief executive officer is beneficial to the business prospects of the Company.

EVENT AFTER THE REPORTING PERIOD

The Directors are not aware of any significant event which had material effect on the Group subsequent to 30 September 2023 and up to the date of this announcement.

SECURITIES TRANSACTIONS BY DIRECTORS

The Company has adopted Rules 5.48 to 5.67 of the GEM Listing Rules as its own code of conduct (“**Code of Conduct**”) regarding securities transactions by the Directors. The Company has confirmed, having made specific enquiry of the Directors, that all the Directors have complied with the Code of Conduct for the nine months ended 30 September 2023 and up to date of this announcement.

AUDIT COMMITTEE AND REVIEW OF QUARTERLY RESULTS

The Group has established an audit committee (the “**Audit Committee**”) pursuant to a resolution of the Directors passed on 12 June 2018 in compliance with Rules 5.28 to 5.33 of the GEM Listing Rules and with written terms of reference in compliance with the CG Code.

The Audit Committee currently consists of one of our non-executive Directors, namely Mr. Lyu Di and two of our independent non-executive Directors, namely Mr. Chan Chi Fung Leo and Dr. Deng Bin and the chairman is Mr. Chan Chi Fung Leo, who holds the appropriate professional qualifications as required under Rules 5.05(2) and 5.28 of the GEM Listing Rules.

The Audit Committee has reviewed the unaudited condensed consolidated financial statements of the Group for the nine months ended 30 September 2023 and is of the opinion that the preparation of such statements complied with the applicable accounting standards, the requirements under the GEM Listing Rules and other applicable legal requirements, and that adequate disclosures had been made.

By order of the Board
Ziyuanyuan Holdings Group Limited
Zhang Junshen
Chairman and Chief Executive Officer

Hong Kong, 13 November 2023

As at the date of this announcement, the executive Directors are Mr. Zhang Junshen (Chairman and Chief Executive Officer) and Mr. Wong Kwok San, the non-executive Director is Mr. Lyu Di and the independent non-executive Directors are Mr. Chan Chi Fung Leo, Mr. Chow Siu Hang and Dr. Deng Bin.

This announcement will remain on the “Latest Listed Company Information” page on the HKEXnews website at www.hkexnews.hk for at least 7 days from the date of its posting and on the website of the Company at www.ziyygroup.com.